Rbx1 Activators
The chemical class of Rbx1 Activators encompasses a diverse group of compounds that indirectly influence the activity of Rbx1 through various biochemical or cellular mechanisms. These chemicals primarily act by modulating the pathways and processes related to ubiquitination and protein degradation, which are key to Rbx1's function. Compounds like MG132 and Lactacystin directly inhibit proteasomal activity, leading to an accumulation of ubiquitinated proteins. This accumulation may influence Rbx1's role in tagging proteins for degradation. Similarly, inhibitors like Pyr-41 target upstream elements of the ubiquitination pathway, specifically the ubiquitin-activating enzyme E1, thus affecting the process in which Rbx1 is a crucial component.
Other compounds in this class, such as tyrosine kinase inhibitors (Nilotinib, Dasatinib) and Hsp90 inhibitors (Geldanamycin), act on signaling pathways or protein stability mechanisms. These actions, although not directly linked to Rbx1, can create a cellular environment that influences the ubiquitination process. For instance, kinase inhibitors may alter the phosphorylation status of proteins that are substrates or regulators of ubiquitination, thereby indirectly affecting Rbx1's activity.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ubiquitin E1 Inhibitor, PYR-41 | 418805-02-4 | sc-358737 | 25 mg | $360.00 | 4 | |
A selective, cell-permeable inhibitor of ubiquitin-activating enzyme E1. By inhibiting E1, Pyr-41 indirectly impacts the ubiquitination process in which Rbx1 is involved. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $165.00 $575.00 | 60 | |
A specific inhibitor of the proteasome. It inhibits the degradation of ubiquitin-conjugated proteins, potentially affecting Rbx1-related ubiquitination processes. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $205.00 $405.00 | 9 | |
A tyrosine kinase inhibitor that can indirectly affect signaling pathways involving Rbx1. While its primary action is on BCR-ABL, it may also influence other pathways relevant to Rbx1. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Another tyrosine kinase inhibitor with a broad spectrum. It may have off-target effects that influence signaling pathways where Rbx1 is involved. | ||||||
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $38.00 $58.00 $102.00 $202.00 | 8 | |
An Hsp90 inhibitor that can destabilize various client proteins, potentially influencing Rbx1 activity indirectly through alterations in protein stability and signaling pathways. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
A kinase inhibitor with multiple targets. Its broad action on different pathways might indirectly affect Rbx1 activity. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $280.00 | 1 | |
Inhibits NEDD8-activating enzyme, affecting cullin-RING ligases (CRLs) of which Rbx1 is a component. This can indirectly influence Rbx1's activity in ubiquitination. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor, known to affect autophagy and protein degradation pathways. This might indirectly influence Rbx1 activity by modulating the cellular environment. | ||||||